Pfizer (PFE) Receivables - Other (2009 - 2023)

Pfizer (PFE) has reported Receivables - Other for 8 consecutive years, with $57.0 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Receivables - Other fell 57.14% year-over-year to $57.0 million in Q2 2023; TTM through Apr 2023 was $57.0 million, a 57.14% decrease from a year earlier, with the FY2021 full-year figure at $53.0 million, down 86.78% from the prior year.
• Receivables - Other was $57.0 million for Q2 2023 at Pfizer, down from $272.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $871.0 million in Q2 2021 and troughed at $53.0 million in Q4 2021.
• A 4-year average of $302.2 million and a median of $234.5 million in 2021 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other slumped 86.78% in 2021 and plunged 37.33% in 2022, its largest moves.
• Over 4 years, Receivables - Other stood at $401.0 million in 2020, then tumbled by 86.78% to $53.0 million in 2021, then surged by 413.21% to $272.0 million in 2022, then slumped by 79.04% to $57.0 million in 2023.
• The last three Receivables - Other figures came in at $57.0 million (Q2 2023), $272.0 million (Q3 2022), and $133.0 million (Q2 2022), per Business Quant data.